Medical specialties

National Kidney Foundation Publishes 23 Recommendations to Move Thousands of Patients from Dialysis to Transplant

Tuesday, July 27, 2021 - 1:04pm

Today, while nearly 100,000 people are on the waitlist for a kidney transplant , only 22,817 Americans received a kidney transplant in 2020.

Key Points: 
  • Today, while nearly 100,000 people are on the waitlist for a kidney transplant , only 22,817 Americans received a kidney transplant in 2020.
  • Research recommendations developed by the panel center on seven key priorities:
    Improve management and readiness of the kidney waitlist.
  • Hispanic or Latino people are 1.3 times more likely than non-Hispanic or non-Latino people to have kidney failure.
  • The National Kidney Foundation (NKF) is the largest, most comprehensive, and longstanding patient-centric organization dedicated to the awareness, prevention, and treatment of kidney disease in the U.S. For more information about NKF, visit www.kidney.org .

ForwardVue Pharma Appoints Bob Katz as Chief Executive Officer

Tuesday, July 27, 2021 - 1:03pm

BOSTON, July 27, 2021 /PRNewswire/ --ForwardVue Pharma names Bob Katz as Chief Executive Officer to advance the pre-clinical development of potent long-acting anti-angiogenic molecules directed against diabetic eye disease and neovascular age related macular degeneration.

Key Points: 
  • BOSTON, July 27, 2021 /PRNewswire/ --ForwardVue Pharma names Bob Katz as Chief Executive Officer to advance the pre-clinical development of potent long-acting anti-angiogenic molecules directed against diabetic eye disease and neovascular age related macular degeneration.
  • Bob Katz is a seasoned life science executive bringing broad, multi-disciplinary expertise in early-stage technology development, clinical applications and successful fundraising.
  • Most recently, Katz was CEO and President of ContraMed where he directed the company from the pre-clinical stage to a successful Phase 3 Clinical Trial and exit.
  • Prior to ContraMed, Katz has held multiple C-level positions at venture-backed startups.

Clinical Study: Kaia Health Computer Vision Technology as Accurate as Physical Therapists in Suggesting Exercise Corrections

Tuesday, July 27, 2021 - 1:00pm

In the study, patients with osteoarthritis of the knee or hip performed a series of exercises while being simultaneously evaluated by computer vision technology and physical therapists.The results showed that physical therapists agreed as much with the exercise corrections suggested by Kaia Health computer vision technology as they did with each other's exercise corrections.

Key Points: 
  • In the study, patients with osteoarthritis of the knee or hip performed a series of exercises while being simultaneously evaluated by computer vision technology and physical therapists.The results showed that physical therapists agreed as much with the exercise corrections suggested by Kaia Health computer vision technology as they did with each other's exercise corrections.
  • Kaia Health computer vision technology, formerly known as Motion Coach, provides automated, real-time exercise feedback by tracking exercise form through the user's smartphone camera.
  • "By integrating computer vision technology with our network of physical therapists, Kaia Health is changing the MSK care paradigm," said Kaia Health U.S. Chief Medical Officer Justin Yang, M.D.
  • Kaia Health was the first to launch mobile computer vision technology for MSK in 2018 and remains the MSK technology market leader.

Ultragenyx Receives Orphan Drug Designation from FDA and European Commission for UX053, an Investigational mRNA-therapy for the Treatment of Glycogen Storage Disease Type III

Tuesday, July 27, 2021 - 1:00pm

The FDA Orphan Drug Designation program provides orphan status to drugs and biologics that are intended for the safe and effective treatment, diagnosis, or prevention of rare diseases that affect fewer than 200,000 people in the U.S.

Key Points: 
  • The FDA Orphan Drug Designation program provides orphan status to drugs and biologics that are intended for the safe and effective treatment, diagnosis, or prevention of rare diseases that affect fewer than 200,000 people in the U.S.
  • Among the benefits of orphan designation in the U.S. are seven years of market exclusivity following FDA approval, waiver or partial payment of application fees, and tax credits for clinical testing expenses conducted after orphan designation is received.
  • Glycogen Storage Disease Type III, or GSDIII, a disease caused by a glycogen debranching enzyme (AGL) deficiency that results in glycogen accumulation in the liver and muscle.
  • The company is led by a management team experienced in the development and commercialization of rare disease therapeutics.

Rhythm Pharmaceuticals to Report Second Quarter 2021 Financial Results on Tuesday, August 3, 2021

Tuesday, July 27, 2021 - 1:00pm

ET on Tuesday, August 3, 2021 to report its second quarter 2021 financial results and provide a corporate update.

Key Points: 
  • ET on Tuesday, August 3, 2021 to report its second quarter 2021 financial results and provide a corporate update.
  • A webcast of the call will also be available under Events & Presentations in the Investor Relations section of the Rhythm website at ir.rhythmtx.com.
  • Rhythm is a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for people living with rare genetic diseases of obesity.
  • Rhythm is advancing a broad clinical development program for setmelanotide in other rare genetic diseases of obesity.

CV Sciences, Inc. Receives NutraIngredients-USA 2021 Product of the Year: Immune Support Award

Tuesday, July 27, 2021 - 1:00pm

SAN DIEGO, July 27, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the Company, CV Sciences, our, us or we), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, announced today that it received NutraIngredients-USA s 2021 Product of the Year: Immune Support Award for its CV Defense product.

Key Points: 
  • SAN DIEGO, July 27, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the Company, CV Sciences, our, us or we), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, announced today that it received NutraIngredients-USA s 2021 Product of the Year: Immune Support Award for its CV Defense product.
  • The active ingredients in CV Defense are backed by hundreds of scientific studies for daily support of barrier immunity, innate immunity, and adaptive immunity.
  • CV Defense by CV Sciences stood out in a crowded category, said Stephen Daniells, PhD, Editor-in-Chief of NutraIngredients-USA.
  • This award also validates our strategic decision to expand our product portfolio beyond the hemp-derived CBD category that we pioneered.

Flor Americas Partners with Biosintex Laboratorios to Supply Cannabinoids for Argentina’s Pharmaceutical Market

Tuesday, July 27, 2021 - 12:17pm

Additionally, Flor Americas will secure Biosintex Laboratorios long-term cannabinoid supply agreements to commercialize its innovative formulations for Argentinas burgeoning medical cannabis market.

Key Points: 
  • Additionally, Flor Americas will secure Biosintex Laboratorios long-term cannabinoid supply agreements to commercialize its innovative formulations for Argentinas burgeoning medical cannabis market.
  • During the past 20 years, Biosintex Laboratorios has earned a reputation for developing and manufacturing world-class pharmaceuticals.
  • Recently, Biosintex Laboratorios received authorization to import CBD from a producer within Flor Americas network.
  • Biosintex Laboratorios is an Argentine pharmaceutical company that develops and manufactures medicinal products with more than 20 years of experience in the market.

Opteev Launches the First-Ever Plug-In Airborne Virus Detector that Immediately Alerts when COVID-19, the Flu and Other Viruses Are Found

Tuesday, July 27, 2021 - 12:30pm

New procedures and technologies are needed to stop the spread of COVID-19 this year while allowing people to enjoy their lives.

Key Points: 
  • New procedures and technologies are needed to stop the spread of COVID-19 this year while allowing people to enjoy their lives.
  • "With ViraWarn, we're making it safer to be together indoors and helping prevent large scale virus transmission in the future."
  • Like a smoke detector monitoring the air and alerting when smoke is detected, ViraWarn monitors the air and immediately alerts when coronavirus particles are detected.
  • The patented sensor technology focuses on the unique electrochemistry of spiked protein viruses, including COVID-19 and influenza, to trigger an alert.

LifeSignals receives FDA 510 (k) Approval for LifeSignals LX1550 Multiparameter Remote Monitoring Platform

Tuesday, July 27, 2021 - 12:00pm

FREMONT, Calif., July 27, 2021 /PRNewswire/ -- LifeSignals Inc., today announced it has received FDA Class II 510 (k) approval for the LifeSignals LX1550 Multiparameter Remote Monitoring Platform.

Key Points: 
  • FREMONT, Calif., July 27, 2021 /PRNewswire/ -- LifeSignals Inc., today announced it has received FDA Class II 510 (k) approval for the LifeSignals LX1550 Multiparameter Remote Monitoring Platform.
  • Clinicians and Care Providers can access the cloud-based remote monitoring dashboard to view patient physiological data and manage alert settings.
  • The Remote Monitoring Platform is designed to enable healthtech companies to rapidly enhance their product and service portfolios to provide vital sign monitoring to the widest possible patient base, from any location.
  • "This FDA 510 (k) approval marks another major milestone in the company's development and mission.

LifeSignals receives FDA 510 (k) Approval for LifeSignals LX1550 Multiparameter Remote Monitoring Platform

Tuesday, July 27, 2021 - 12:00pm

FREMONT, Calif., July 27, 2021 /PRNewswire/ -- LifeSignals Inc., today announced it has received FDA Class II 510 (k) approval for the LifeSignals LX1550 Multiparameter Remote Monitoring Platform. This follows recent CE marking and is further validation of LifeSignals' drive to create innovative wireless platforms which can be used by clinicians for the continuous collection of patient physiological data at home and in healthcare settings.

Key Points: 
  • FREMONT, Calif., July 27, 2021 /PRNewswire/ -- LifeSignals Inc., today announced it has received FDA Class II 510 (k) approval for the LifeSignals LX1550 Multiparameter Remote Monitoring Platform.
  • Clinicians and Care Providers can access the cloud-based remote monitoring dashboard to view patient physiological data and manage alert settings.
  • The Remote Monitoring Platform is designed to enable healthtech companies to rapidly enhance their product and service portfolios to provide vital sign monitoring to the widest possible patient base, from any location.
  • Our focus now is to rapidly introduce low-cost remote vital sign monitoring to US healthtech companies looking to expand their services and improve patient care."